Outcomes among inpatients with cirrhosis and
Cirrhosis
Clostridioides difficile infection
National Inpatient Sample
acute kidney injury
Journal
Annals of gastroenterology
ISSN: 1108-7471
Titre abrégé: Ann Gastroenterol
Pays: Greece
ID NLM: 101121847
Informations de publication
Date de publication:
Historique:
received:
10
11
2020
accepted:
22
03
2021
entrez:
3
9
2021
pubmed:
4
9
2021
medline:
4
9
2021
Statut:
ppublish
Résumé
Patients with cirrhosis are at increased risk of The Nationwide Inpatient Sample from 2016-2017 identified 8245 hospitalized patients with a concurrent diagnosis of cirrhosis and CDI. Our primary outcome was in-hospital all-cause mortality. Secondary outcomes were length of stay (LOS), hospitalization charges and costs, shock, sepsis, acute kidney injury (AKI), intensive care unit (ICU) admission, and home discharge. There was no significant difference in all-cause in-hospital mortality between patients with cirrhosis compared to patients without cirrhosis (adjusted odds ratio [aOR] 1.31, 95% confidence interval [CI] 0.89-1.93; P=0.16). Patients with cirrhosis had a slightly but statistically significantly longer mean LOS (+0.57 days, P=0.001). The adjusted difference in mean hospitalization charges was greater in patients with cirrhosis ($+4094, 95%CI $1080-7108; P=0.008), as was the mean hospitalization cost ($+1349, 95%CI $600-2098; P<0.001). There was no difference in the likelihood of sepsis, ICU admission, or home discharge between the groups. Patients with cirrhosis were significantly less likely to develop AKI (aOR 0.82, 95%CI 0.72-0.93; P=0.003). Mortality outcomes associated with CDI have improved over time. Patients with cirrhosis continue to exhibit greater LOS and hospital costs.
Sections du résumé
BACKGROUND
BACKGROUND
Patients with cirrhosis are at increased risk of
METHODS
METHODS
The Nationwide Inpatient Sample from 2016-2017 identified 8245 hospitalized patients with a concurrent diagnosis of cirrhosis and CDI. Our primary outcome was in-hospital all-cause mortality. Secondary outcomes were length of stay (LOS), hospitalization charges and costs, shock, sepsis, acute kidney injury (AKI), intensive care unit (ICU) admission, and home discharge.
RESULTS
RESULTS
There was no significant difference in all-cause in-hospital mortality between patients with cirrhosis compared to patients without cirrhosis (adjusted odds ratio [aOR] 1.31, 95% confidence interval [CI] 0.89-1.93; P=0.16). Patients with cirrhosis had a slightly but statistically significantly longer mean LOS (+0.57 days, P=0.001). The adjusted difference in mean hospitalization charges was greater in patients with cirrhosis ($+4094, 95%CI $1080-7108; P=0.008), as was the mean hospitalization cost ($+1349, 95%CI $600-2098; P<0.001). There was no difference in the likelihood of sepsis, ICU admission, or home discharge between the groups. Patients with cirrhosis were significantly less likely to develop AKI (aOR 0.82, 95%CI 0.72-0.93; P=0.003).
CONCLUSIONS
CONCLUSIONS
Mortality outcomes associated with CDI have improved over time. Patients with cirrhosis continue to exhibit greater LOS and hospital costs.
Identifiants
pubmed: 34475744
doi: 10.20524/aog.2021.0646
pii: AnnGastroenterol-34-721
pmc: PMC8375645
doi:
Types de publication
Journal Article
Langues
eng
Pagination
721-727Informations de copyright
Copyright: © Hellenic Society of Gastroenterology.
Déclaration de conflit d'intérêts
Conflict of Interest: None
Références
Circ Cardiovasc Qual Outcomes. 2017 Jul;10(7):
pubmed: 28705865
Clin Gastroenterol Hepatol. 2019 Jan;17(2):307-321
pubmed: 30099098
Hepatology. 2012 Dec;56(6):2328-35
pubmed: 22806618
Clin Infect Dis. 2018 Mar 19;66(7):e1-e48
pubmed: 29462280
AMA J Ethics. 2015 Nov 01;17(11):1046-52
pubmed: 26595246
Liver Int. 2019 Jul;39(7):1263-1270
pubmed: 30790420
Liver Int. 2015 Feb;35(2):391-400
pubmed: 25039438
Clin Gastroenterol Hepatol. 2017 Jun;15(6):953-954
pubmed: 28126426
Dig Dis Sci. 2015 Oct;60(10):3124-9
pubmed: 25986524
Am J Gastroenterol. 2010 Jan;105(1):114-6
pubmed: 20054307
Eur J Gastroenterol Hepatol. 2019 May;31(5):586-592
pubmed: 30741727
Am J Gastroenterol. 2010 Jan;105(1):106-13
pubmed: 19844204
J Clin Gastroenterol. 2013 Jul;47(6):481-4
pubmed: 23059411
Clin Infect Dis. 2012 Aug;55 Suppl 2:S88-92
pubmed: 22752870
Dig Dis Sci. 2020 Feb;65(2):632-638
pubmed: 31440997
Sci Rep. 2018 Jul 2;8(1):9969
pubmed: 29967363
J Gastroenterol Hepatol. 2018 Jun;33(6):1227-1233
pubmed: 29205514
Anaerobe. 2012 Oct;18(5):489-97
pubmed: 22940065
Hepatology. 2009 Dec;50(6):2022-33
pubmed: 19885876
J Clin Gastroenterol. 2013 May-Jun;47(5):e50-4
pubmed: 23090041